Weber F, Brodde O E, Anlauf M, Bock K D
Clin Exp Hypertens A. 1983;5(2):225-38. doi: 10.3109/10641968309048823.
To determine the beta-adrenoceptor subtype controlling renin release from the kidneys, several beta-adrenoceptor subtype selective agonists and antagonists were administered to 15 healthy volunteers. While isoprenaline infusion (1, 2 and 4 micrograms/min for 5 min each) markedly increased plasma renin activity (PRA), the beta 2-selective agonist fenoterol failed to change PRA. The isoprenaline induced rise in PRA could be completely prevented by the beta 1-selective antagonists metoprolol (10 mg i.v. 45 min prior to isoprenaline infusion) and betaxolol (5 mg i.v. 45 min prior to infusion) indicating that renin release is mediated by beta 1-adrenoceptors. Binding studies with the highly specific beta-adrenoceptor radioligand (+/-)-125iodocyanopindolol demonstrated that membranes from human kidney cortical slices contain predominantly, if not exclusively, beta 1-adrenoceptors. These in vivo and in vitro results support the view that the beta-adrenoceptor mediating renin release from the human kidney is of the beta 1-subtype.
为了确定控制肾脏肾素释放的β-肾上腺素能受体亚型,对15名健康志愿者施用了几种β-肾上腺素能受体亚型选择性激动剂和拮抗剂。静脉输注异丙肾上腺素(1、2和4微克/分钟,各持续5分钟)可显著增加血浆肾素活性(PRA),而β2选择性激动剂非诺特罗未能改变PRA。异丙肾上腺素诱导的PRA升高可被β1选择性拮抗剂美托洛尔(静脉注射10毫克,在输注异丙肾上腺素前45分钟)和倍他洛尔(静脉注射5毫克,在输注前45分钟)完全阻断,这表明肾素释放是由β1-肾上腺素能受体介导的。使用高度特异性的β-肾上腺素能受体放射性配体(±)-125碘氰吲哚洛尔进行的结合研究表明,人肾皮质切片的膜中主要(如果不是唯一)含有β1-肾上腺素能受体。这些体内和体外研究结果支持这样一种观点,即介导人肾肾素释放的β-肾上腺素能受体是β1亚型。